Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 12, 2009, Pages 5297-5299

  Mariné, Marçal ^a   Pastor, F Javier ^a   Sahand, Ismail H ^b   Pontón, José ^b   Quindós, Guillermo ^b   Guarro, Josep ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; CYCLOPHOSPHAMIDE; ECHINOCANDIN; FLUOROURACIL; MICAFUNGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CANDIDA DUBLINIENSIS; CLINICAL EVALUATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; FUNGUS GROWTH; FUNGUS ISOLATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INVASIVE CANDIDIASIS; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; ECHINOCANDINS; LIPOPEPTIDES; MALE; MICE;

EID: 71249150316     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00980-09     Document Type: Article

References (15)

1. Andes, D. R., D. J. Diekema, M. A. Pfaller, K. Marchillo, and J. Bohrmueller. 2008. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother. 52:3497-3503.
2. Andes, D., D. J. Diekema, M. A. Pfaller, R. A. Prince, K. Marchillo, J. Ashbeck, and J. Hou. 2008. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother. 52:539-550.
3. Clemons, K. V., M. Espiritu, R. Parmar, and D. A. Stevens. 2006. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob. Agents Chemother. 50:1293-1297.
4. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard - third edition. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Fanci, R. 2009. Breakthrough Candida dubliniensis fungemia in an acute myeloid leukemia patient during voriconazole therapy successfully treated with caspofungin. J. Chemother. 21:105-107.
6. Fleischhacker, M., C. Radecke, B. Schulz, and M. Ruhnke. 2008. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur. J. Clin. Microbiol. Infect. Dis. 27:127-131.
7. Hajdu, R., R. Thompson, J. G. Sundelof, B. A. Pelak, F. A. Bouffard, J. F. Dropinski, and H. Kropp. 1997. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2339-2344.
8. Isham, N. C., and M. A. Ghannoum. 2007. Voriconazole and caspofungin cidality against non-albicans Candida spp. Infect. Dis. Clin. Pract. 15:250-253.
9. Jacobsen, M. D., J. A. Whyte, and F. C. Odds. 2007. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. Antimicrob. Agents Chemother. 51:1882-1884.
10. Mariné, M., C. Serena, B. Fernández-Torres, F. J. Pastor, and J. Guarro. 2005. Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata. Antimicrob. Agents Chemother. 49:4757-4759. (Pubitemid 41552611)
11. Marriott, D., M. Laxton, and J. Harkness. 2001. Candida dubliniensis candidemia in Australia. Emerg. Infect. Dis. 7:479.
12. Mubareka, S., D. C. Vinh, and S. E. Sanche. 2005. Candida dubliniensis bloodstream infection: a fatal case in a lung transplant recipient. Transplant. Infect. Dis. 7:146-149.
13. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 blood-stream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.
14. Pinjon, E., G. P. Moran, D. C. Coleman, and D. J. Sullivan. 2005. Azole susceptibility and resistance in Candida dubliniensis. Biochem. Soc. Trans. 33:1210-1214.
15. van Hal, S. J., D. Stark, J. Harkness, and D. Marriott. 2008. Candida dubliniensis meningitis as delayed sequela of treated C. dubliniensis fungemia. Emerg. Infect. Dis. 14:327-329.